Canada's Drug Agency (CDA-AMC) posted a revised draft recommendation on 16 July 2026 advising that public drug plans reimburse lecanemab (Leqembi) for early Alzheimer's disease with conditions, reversing the draft its Canadian Drug Expert Committee (CDEC) issued on 19 February 2026 advising against funding. The conditions restrict treatment to adults with mild cognitive impairment or mild dementia due to Alzheimer's disease who are ApoE4 noncarriers or heterozygotes with amyloid pathology confirmed by PET or cerebrospinal fluid testing, require prescribing by specialists and MRI monitoring for amyloid-related imaging abnormalities, and require a substantial price reduction, the committee having judged the drug not cost-effective at the price submitted. The feedback window closed on 30 July 2026 and a final recommendation is pending. CDA-AMC recommendations are advice to the provinces and territories, not decisions; each jurisdiction decides what it lists.
What changed was the evidence file, not the trial. Lecanemab's pivotal study, Clarity AD, was an 18-month randomised, double-blind, placebo-controlled phase 3 trial in 1,795 people; CDEC considered post-hoc results in the 1,521 participants who were ApoE4 noncarriers or heterozygotes, where the adjusted mean difference in the Clinical Dementia Rating Sum of Boxes was 0.579 points in favour of lecanemab (95% confidence interval 0.811 to 0.347) on an 18-point scale. At Eisai's request the committee reconsidered in June 2026, informed by 48-month findings from the Clarity AD open-label extension, in which everyone receives the drug and the comparison is with matched external controls from the ADNI dataset rather than with randomised placebo. Those preliminary open-label findings, reported by investigators including Eisai employees, describe widening differences in CDR-SB of 0.52 at 18 months, 1.01 at 36 months and 1.75 at 48 months, with no new safety signals.
The licence and the money have now separated in Canada, as they have in England. Health Canada authorised lecanemab under a Notice of Compliance with Conditions with a decision date of 24 October 2025, and authorised donanemab (Kisunla) with a decision date of 30 April 2026, announced by Lilly Canada on 4 May 2026. A CMAJ practice article published on 28 June 2026 put the expected Canadian cost of lecanemab at $35,000 to $40,000 per patient per year, before diagnostic testing, infusion services and serial MRI, and noted that Quebec's INESSS advised against coverage in December 2025. In England, NICE's final draft guidance of June 2025 did not recommend either drug for the NHS.
The committee did not declare the argument settled. In its draft it concluded that lecanemab "justifies a positive recommendation despite the uncertainty in the clinical value", language that concedes how much is still unknown. Confidential price negotiation would follow any final positive recommendation, and provincial listing after that.